Page 6 - Safina News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Bayer s blood thinner fails phase 3, denting $5B sales forecast

Bayer s blood thinner fails phase 3, denting $5B sales forecast
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

Blackstone life sciencesBristol myers squibbAnthos therapeuticsBlackstone life

Asundexian Phase 3 AF Study Halted for Lack of Efficacy

The phase 3 OCEANIC-AF trial of the factor XI inhibitor asundexian (Bayer) has been stopped early owing to inferior efficacy vs apixaban in preventing stroke and systemic embolism in patients with AF.

United statesNorth carolinaNoacs doacsChristian rommelManesh patelGlobal head of researchDuke clinical research instituteMedscape cardiologyGlobal headChristian ruffAtrial fibrillationF atrial fibrillationAnticoagulation therapyErebrovascular accidentVa cerebrovascular accidentAnti thrombotics

Bayers Halts Asundexian AFib Trial, OCEANIC-AF, for Inferior Efficacy

Bayer has announced the IDMC for OCEANIC-AF trial has recommended the trial be discontinued as a result of inferior efficacy.

Christian rommelData monitoring committeeGlobal head of researchCommittee of bayer ag pharmaceutical divisionIndependent data monitoring committeeExecutive committeeGlobal head

New asundexian Phase III study to include patients with atrial fibrillation ineligible for oral anticoagulant treatment

WHIPPANY, N.J. (BUSINESS WIRE) Nov 10, 2023

United statesXia fxiaRoxana mehranChristian rommelHaass internationalDrug administrationJournal of the american heart associationInterventional cardiovascular researchInternational society on thrombosisBayer agGlobal head of researchExecutive committeeGlobal headClinical trialsIcahn schoolInternational society

New asundexian Phase III study to include patients with atrial fibrillation ineligible for oral anti

New study includes patients aged ≥65 years with atrial fibrillation (AF) at high risk for ischemic stroke or systemic embolism who are deemed ineligible for oral anticoagulant (OAC) treatment due to increased risk of bleedingOCEANIC-AFINA, the latest Phase III study in the OCEANIC clinical trial program, will invest.

United statesRoxana mehranChristian rommelXia fxiaBayer agHaass internationalJournal of the american heart associationInterventional cardiovascular researchGlobal head of researchInternational society on thrombosisDrug administrationExecutive committeeGlobal headClinical trialsIcahn schoolInternational society